

MBST Award 2020 for Dr. Bibiane Steinecker-Frohnwieser · Graz

At the 3rd Wetzlar Medical Symposium about MBST magnetic resonance therapy in Wetzlar, Priv.-Doz. Mag. Dr. rer. nat. Bibiane Steinecker-Frohnwieser was awarded for her activities in studies and research about MBST therapy.

MBST Award for Dr. Steinecker-Frohnwieser

On the 6th of March 2020 at the third international medical symposium, Priv.-Doz. Mag. Dr. rer. nat. Bibiane Steinecker-Frohnwieser received an MBST Award. She was honoured for her long-term academic research in the exploration of the active principle of therapeutically used MBST magnetic resonance technology. In Wetzlar, she also gave a lecture about the newest findings in the research on human chondrocytes.



Priv.-Doz. Mag. Dr. rer. nat. Bibiane Steinecker-Frohnwieser

Changes in the miRNA Profile and Hypoxic Behaviour of Human chondrocytes by NMRT · NMRT stands for MBST therapy

EULAR (Annual European Congress of Rheumatology) is an annual congress and an important event in the field of rheumatology. It is a unique opportunity to get current information on the state of research in this field. Priv.-Doz. Mag. Dr. rer. nat. Bibiane Steinecker-Frohnwieser presented a conference paper about the topic mentioned above. A detailed study of the mechanisms of NMRT shows a modulating effect on the miRNA, its regulatory units and the chondrocytes under hypoxic conditions. The current results confirm earlier findings which showed that NMRT can counteract changes induced by IL-1 β which means that the effect of pain reduction in the case of OA by NMRT may be caused by its effect on inflammatory mechanisms.

Together with Univ.-Doz. Dr. Werner Kullich, Bibiane Steinecker-Frohnwieser has done a great deal of research into the effect of magnetic resonance on cartilage cells. „There are changes, information about inflammatory mechanisms that we have to look into“, says Kullich. They were able to show that after one hour of magnetic resonance exposition, a statistically significant decrease of intracellular calcium is noticeable in Cal-78 cells which may be connected to the reduction of pain that was observed in clinical studies.

About MedTec Medizintechnik GmbH

Founded in 1998, MedTec Medizintechnik GmbH from Wetzlar has developed from a pioneer to world market leader in the field of therapeutically used MBST magnetic resonance technology. MedTec develops, produces and distributes the worldwide unique and patented technology that is used in MBST therapy system for human, veterinary and aesthetic medicine. Doctors, specialist, medical centres, hospitals, clinics and universities put their trust in the MBST therapy system today – not only in Germany and Europe but worldwide. It is MedTec's vision to enable a healthy, active and pain-free life for patients of nearly every age with its therapeutically used MBST technology. The MBST magnetic resonance therapy achieves that in the treatment of various degenerative diseases and injuries of the musculoskeletal system without needing drugs, injections, infusions, pain killers or surgical interventions. More than 1,000,000 hours of therapy have been applied with the MBST magnetic resonance technology so far without any side effects or interactions becoming known. MedTec Medizintechnik GmbH stands for global leadership of market and technology with its worldwide patented therapeutically used MBST magnetic resonance technology.

Press contact and order of photo material:

MedTec Medizintechnik GmbH
Sportparkstraße 9
D-35578 Wetzlar

Guido Finkes · CMO
Sales & Marketing Director

Caroline Ebinger
PR & Marketing Consultant

Phone: 06441 · 679 18 - 29
Fax: 06441 · 679 18 - 19
eMail: marketing@mbst.de
www.mbst.de

